Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Kite's management team has a proven track record of building successful biotechnology companies and developing cutting edge oncology treatments. Additionally, the company's Scientific Advisory Board is comprised of leaders who have guided the advancement of novel cancer immunotherapies.